Stay updated on Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.

Latest updates to the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe RELATIVITY-047 record now displays details of the study comparing relatlimab plus nivolumab with nivolumab alone for advanced melanoma, including its design, eligibility criteria, results measures, and locations. It also provides study documents and related publications.SummaryDifference100%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces NIH’s terminology transition, saying federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) and linking to updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study content. This blocks access to the RELATIVITY-047 study details and related information.SummaryDifference18%

Stay in the know with updates to Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.